Table 2 Demographics of study participants
From: Preliminary results of Preserflo Microshunt versus Preserflo Microshunt and Ologen implantation
Demographics | n | ||
|---|---|---|---|
No. of patients | 50 | ||
No. of female patients | 33 | ||
Age (years) | 76.13 ± 10.08 | ||
No. of male patients | 17 | ||
Age (years) | 79.00 ± 7.94 | ||
No. of eyes operated total (POAG refractory to medical treatment) | 50 | ||
Baseline MD (dB) total | −13.31 ± 7.93 | ||
Advanced POAG, Baseline MD (dB) (n = 35) | −20.50 ± 6.38 | ||
Moderate POAG, Baseline MD (dB) (n = 15) | −7.37 ± 0.71 | ||
Group A (n) | Group B (n) | Intergroup variable comparison t-test, P < 0.05 (95% CI) | |
No. of eyes operated total | 25 | 25 | N.A |
No. of pseudophakic eyes | 25 | 25 | N.A |
Age (years) | 77.58 ± 7.62 | 75.64 ± 12.61 | 0.88 (−6.15 to 5.32) |
Baseline MD (dB) | −13.15 ± 8.53 | −13.47 ± 7.44 | 0.84 (−4.57 to 3.78) |
Baseline average RNFL thickness (μm) | 65.04 ± 8.03 | 64.54 ± 10.67 | 0.52 (−3.63 to 6.78) |
Baseline IOP (mmHg) | 23.52 ± 5.78 | 26.04 ± 8.76 | 0.26 (−1.93 to 6.77) |
Baseline antiglaucoma agents | 2.52 ± 0.91 | 2.58 ± 0.82 | 0.36 (−0.38 to 0.98) |
Baseline DCVA (Snellen) | 0.64 ± 0.24 | 0.58 ± 0.27 | 0.43 (−0.23 to 0.10) |